Nasdaq · CIK 0001534525
XBIO Xenetic Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Apr 23, 2026.
Xenetic Biosciences, Inc. (XBIO) has 9 SEC Form 4 filings on file from 5 insiders, the latest filed on Apr 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Xenetic Biosciences, Inc., scored.
Transactions
Every row filed, 9 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | James F Parslow Interim CEO and CFO | AGrant or award Common Stock10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Apr 23, 2026 |
| Dec 31, 2025 | Grigory G. Borisenko director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Jan 5, 2026 |
| Dec 31, 2025 | Firdaus J. Dastoor director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Jan 5, 2026 |
| Dec 31, 2025 | Roger D. Kornberg director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Jan 5, 2026 |
| Dec 31, 2025 | Alexey Andreevich Vinogradov director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Jan 5, 2026 |
| Dec 11, 2024 | Grigory G. Borisenko director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Dec 13, 2024 |
| Dec 11, 2024 | Firdaus J. Dastoor director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Dec 13, 2024 |
| Dec 11, 2024 | Roger D. Kornberg director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Dec 13, 2024 |
| Dec 11, 2024 | Alexey Andreevich Vinogradov director | AGrant or award Stock Optionsderivative | +2,500 | $0.00 | $0 | 2,500 | Dec 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Grigory G. Borisenkodirector
- Firdaus J. Dastoordirector
- Roger D. Kornbergdirector
- James F ParslowInterim CEO and CFO
- Alexey Andreevich Vinogradovdirector
Questions about XBIO
Answered from the filings on this page, as of the latest one.
Are insiders buying XBIO?
No. In the last 90 days no insider at Xenetic Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade XBIO on the open market?
No open-market trade has been scored at Xenetic Biosciences, Inc.. The latest Form 4 on file was filed on Apr 23, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Xenetic Biosciences, Inc.?
5 people have filed a Form 4 at Xenetic Biosciences, Inc., among them Grigory G. Borisenko (director), Firdaus J. Dastoor (director), Roger D. Kornberg (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.